The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with ...

Single-dose CAR-T therapy potentially curative in multiple myeloma by Justin Jackson, Phys.org edited by Sadie Harley, reviewed by Robert Egan Editors' notes ...

For patients newly diagnosed with multiple myeloma, optimal outcomes start with a clear set of goals. "The primary goals of initial treatment are straightforward: relieve symptoms like anemia ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

Key Takeaways The narrative uses a mountain ascent as a metaphor for seeking peace and purpose after a multiple myeloma diagnosis. A spiritual sanctuary provides solace, emphasizing the importance of ...